Echinomycin (NSC 526417) in Squamous-Cell Carcinoma of the Cervix
- 1 June 1990
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 13 (3) , 191-193
- https://doi.org/10.1097/00000421-199006000-00002
Abstract
Twenty-eight evaluable patients with advanced or recurrent squamous-cell carcinoma of the cervix were treated with 1,500 .mu.g/m2 of echinomycin every 4 weeks. All patients had prior chemotherapy. Two patients had partial responses (7% response, 95% confidence interval for response of 1 to 24%). The major toxicity was nausea and vomiting. Myelosuppression and other toxicity were modest. Echinomycin, at this dose and schedule, displays minimal activity in patients with squamous-cell carcinoma of the cervix who had prior chemotherapy.This publication has 1 reference indexed in Scilit: